source
- Sensible Bio raises $47 million Series A to build mRNA therapy manufacturing platformSensible Biotechnologies announced it has closed a $47 million Series A financing round. The capital will be used to develop its proprietary manufacturing platform for mRNA based therapies. The fu…
- Epicrispr reports encouraging early data from EPI-321 in 12 patients with FSHDEpicrispr Biotechnologies released updated data on its epigenetic editing therapy EPI-321 aimed at treating facioscapulohumeral muscular dystrophy (FSHD). The company has now dosed twelve particip…